Advertisement

Letrozole versus anastrozole in postmenopausal women with chemotherapy-refractory negative HER-2 metastatic breast cancer: a randomised, multicentre, open-label, non-inferiority phase 3 study

 
crossMark
 
Research Article 
dx.doi.org/10.18081/2333-5106/014-4/431-440
American Journal of BioMedicine Volume 2, Issue 4, pages 431–440
Received December 15, 2013; accepted March 01, 2014; published April 29, 2014

Alex J Danielsona, Nasser Ghaly Yousifa, Dan G. Wanga, b,  Alexey F Maltzmana, Howell G Johnstona, Aman S Gomeza, Han Leeamail of corresponding author

Abstract

Breast cancer is the most common form of cancer affecting elderly women in worldwide, although the usually reported incidence of breast cancer is close to 50% in women 65 years or older, reaching 47% after 70 years in the updated Surveillance, Epidemiology, and End Results (SEER) database. Third-generation aromatase inhibitors are being considered as an alternative to tamoxifen as first-line therapy for advanced breast cancer. These newer therapies are more expensive, and will gain greater acceptance if they can demonstrate cost-effectiveness. We assessed the efficacy and toxicity of letrozole versus anastrozole in these patients. For this randomized, open-label, phase 3 head-to-head study, we enrolled patients (from centers in North America, Europe, Africa, Australia and Asia) aged 65 years or older with chemotherapy-refractory metastatic breast cancer, ECOG performance status of 2 or less. Using a computer-generated randomization sequence, we assigned patients to receive letrozole or anastrozole. The primary endpoint was overall survival assessed for non-inferiority (retention of ≥50% of the letrozole treatment effect; historical hazard ratio [HR] for letrozole vs best anastrozole 0·55). The data from this study show that letrozole is at least as effective as anastrozole as first-line therapy of metestatic breast cancer in postmenopausal women. A total of 56.7% of patients in the letrozole group and 41.3% of patients in the anastrozole group gained clinical benefit from treatment.

Keywords: Breast cancer; SEER; Letrozole; anastrozole; ECOG; Chemotherapy-refractory

Copyright © 2014 by The American Society for BioMedicine and BM-Publisher, Inc.

Article citationReferencesFull-Text/PDFFeedback
The citation data is computed by the following citation measuring services:

Google scholarcitedby

References

1. Goldhirsch A, Glick JH, Gelber RD, et al: Meeting highlights: International expert consensuson the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16:1569-1583. [Abstract/Full-Text]

2. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24(34):5373-5380. [Abstract/Full-Text]

3. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003.CA Cancer J Clin 2003;53:5–26. [CrossRef]

4. Bross PF, Baird A, Chen G, et al. Fulvestrant in postmenopausal women with advanced breast cancer. Clin Cancer Res 2003;9:4309–17. [Abstract/Full-Text]

5. Speirs V, Carder PJ, Lane S, et al. Oestrogen receptor β: what it means for patients with breast cancer.Lancet Oncol 2004;5:174–81. [CrossRef]

6. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365:1687-1717. [CrossRef]

7. Winer EP, Hudis C, Burstein HJ, et al: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 2004; 23:619-629. [CrossRef]

8. Lane HA, Lebwohl D. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program. Semin Oncol 2006;33:S18–25. [Medline]

9. Bottini A, Generali D, Brizzi MP, et al. A Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 2006;24:3623–8. [Abstract/Full-Text]

10. Tokunaga E, Kimura Y, Mashino K, et al. Activation of PI3K/AKT signaling and hormone resistance in breast cancer. Breast Cancer 2006;13:137–44. [CrossRef]

11. NG Yousif, FG Al-amran.  Novel Toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice. BMC cardiovascular disorders 2011;11(1):62. [Abstract/Full-Text]

12. Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005;23:5108–16. [Abstract/Full-Text]

13. Generali D, Fox SB, Berruti A, et al. Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer. Clin Cancer Res. 2007;13(2 pt 1):550-558. [Abstract/Full-Text]

14. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48-e72. [Medline]

15. NG Yousif, Al-Matwari M, Deb AA, Mousa HJ. Overexpression of Notch-1 induced tamoxifen resistance through down regulation of ESR1 in positive estrogen receptor breast cancer. journal of clinical oncology 2012;30 (suppl 5). [Google Scholar]

16. Coombes R, Hall E, Gibson L, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:10811092. doi:10.1056/NEJMoa040331. [Google Scholar]

17. Goss P, Ingle J, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:17931802. doi:10.1056/NEJMoa032312 [Abstract/Full-Text] 

18. Partridge AH, LaFountain A, Mayer E, et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008;26:556562. doi:10.1200/JCO.2007.11.5451. [Abstract/Full-Text]

19. NG Yousif.  Fibronectin promotes migration and invasion of ovarian cancer cells through up-regulation of FAK–PI3K/Akt pathway. Cell biology international 2013; 38(1), 85-91. [Abstract/Full-Text]

20. Park IH, Lee YS, Lee KS, et al. Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer. Cancer Chemother Pharmacol 2011;68:1263-1271. [CrossRef]

READ THE FULL ARTICLE

limited access

1. Access this article  through your login credentials or your institution

Get Access

2. Access this article through OpenAthens/Sign in

3. Purchase this article at rate $55.00 and received Full-Text/PDF
You will have online immediate access to article following the completion of this purchase and you may download and print a copy of each article for your personal use. Use the coding below to purchase your article as PDF by credit card, debit card, payball will be asked to supply your billing card information. Before continue with your purchase please read carefully the AJBM terms and conditions of purchase.

Purchase Article

 For any technique error please contact us and will be response to sending purchase article by email.

Thank you for visiting American Journal of BioMedicine.  * = Required fields

[gravityform id=”6″ name=”Feedback”]

American Journal of Biomedicine © 2017 Frontier Theme
%d bloggers like this: